Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9588 USD | -6.00% | +36.00% | +67.39% |
May. 13 | Transcript : Vaxart, Inc., Q1 2024 Earnings Call, May 13, 2024 | |
May. 13 | Vaxart, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Number of employees: 109
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Oral Recombinant Protein Vaccines
100.0
%
| 0 | 100.0 % | 7 | 100.0 % | +6,796.26% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 7 | 100.0 % | +6,796.26% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Sean Tucker
FOU | Founder | - | 03-12-31 |
Phillip Eric Lee
DFI | Director of Finance/CFO | 37 | 22-12-18 |
Michael Finney
CHM | Chairman | 65 | 07-06-30 |
James Cummings
CTO | Chief Tech/Sci/R&D Officer | - | 21-09-26 |
Chief Tech/Sci/R&D Officer | - | 22-08-30 | |
Edward Berg
LAW | General Counsel | - | 22-02-13 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Yedid
BRD | Director/Board Member | 66 | 19-10-24 |
Elaine Heron
BRD | Director/Board Member | 76 | 22-08-24 |
Michael Finney
CHM | Chairman | 65 | 07-06-30 |
Sean Tucker
FOU | Founder | - | 03-12-31 |
David Wheadon
BRD | Director/Board Member | 66 | 21-04-20 |
Director/Board Member | 73 | 22-08-03 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 177,502,934 | 174,833,551 ( 98.50 %) | 664,923 ( 0.3746 %) | 98.50 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+67.39% | 170M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- VXRT Stock
- Company Vaxart, Inc.